Recombinant Varicella Zoster Virus Glycoprotein E

• Herpes zoster after recombinant herpes zoster vaccination - Immediate post-RHZ-vaccination evolution of CMI, HMI and lymphocyte count and ty… Pending
  2025-521547-20-00 Phase IV 1 country Centre hospitalier universitaire de Liege
• Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla… Recruiting
  2023-507746-83-00 Phase III 12 countries Merck Healthcare KGaA
• A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia… Recruiting
  2025-524944-37-00 Phase IV 1 country Gentofte Hospital; GlaxoSmithKline Biologicals
• A phase IV trial of Shingrix on incident dementia diagnosis in adults aged ≥76 years in Finland Recruiting
  2025-524598-17-00 Phase IV 1 country GlaxoSmithKline Biologicals
• Characterization of the immune response in immunosuppressed patients with rheumatic diseases, including to the recombinant zoster vaccine Recruiting
  2024-518190-34-00 Phase IV 1 country Centre Hospitalier Universitaire De Toulouse
• Safety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis Recruiting
  2024-512881-32-00 Phase IV 1 country Justus-Liebig-Universitaet Giessen
• Immune response to the recombinant Zoster Vaccine in people living with HIV over 50 years of age compared to non-HIV age- and gender-matched… Ended
  2023-504482-23-00 Phase II 1 country Centre Hospitalier Universitaire De Bordeaux
• A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults. Ended
  2023-505255-51-00 Phase III 8 countries GlaxoSmithKline Biologicals
• PREPARE-iVAC Ended
  2023-503894-39-00 Phase III/IV 1 country Universitair Medisch Centrum Groningen

Showing 1–9 of 9 trials